Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06720558

Effects of a Placebo Probiotic on Gut Health and General Well-being in Individuals With Mild Gastrointestinal Symptoms

A 3-week Randomized Controlled Trial on the Efficacy of a Placebo Probiotic in Rebalancing Gut Health and Fostering Physical and Emotional Well-being in Individuals With Mild Gastrointestinal Symptoms

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
30 (estimated)
Sponsor
Catholic University of the Sacred Heart · Academic / Other
Sex
All
Age
20 Years – 65 Years
Healthy volunteers
Accepted

Summary

The present study is aimed at exploring whether positive expectations of receiving a three-week treatment with a probiotic supplement (in fact a placebo) improve symptoms of gastrointestinal distress and promote physical and emotional well-being in healthy individuals with mild gastrointestinal symptoms. At first, a comparison is planned between (1) a classic deceptive placebo manipulation (Deceptive Placebo group, DP), and (2) a control condition (Control group, C), in which no placebo substance will be administered. After the three-week waiting list, the Control group will be invited to take the placebo probiotic pills in an "open-label" fashion (Open Label Placebo, OLP). Specifically, participants will be informed that the pills are inert placebos. An exploratory analysis will help to clarify whether the OLP paradigm leads to significant effects, based on a within-group (C- OLP) and between-group comparison (DP-OLP).

Conditions

Interventions

TypeNameDescription
OTHERPlacebo probioticThree-week consumption of placebo probiotic capsules passed off as being actual probiotics
OTHEROpen-Label Placebo probioticParticipants of the Control group will be switched to this condition after three weeks and receive placebo probiotic capsules for the following three-weeks of no intervention. Specifically, they will be honestly informed that the capsules are inert placebos.
OTHERControl-no treatmentFor the first three weeks, the Control group will not be exposed to any intervention.

Timeline

Start date
2024-11-20
Primary completion
2025-04-01
Completion
2025-04-01
First posted
2024-12-06
Last updated
2024-12-06

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT06720558. Inclusion in this directory is not an endorsement.